3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Lymphoid
1
Conditions
Polycythemia Vera
2
Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
1
Relapsed Pediatric Solid Tumor
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Blood Stem Cell Transplantation
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Bronchiolitis Obliterans Syndrome
1
Interventions
pegaspargase
14
Etoposide
11
Dexamethasone
11
Gemcitabine
10
spartalizumab
6
Oxaliplatin
4
sintilimab
3
Radiotherapy
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Methotrexate
3
Asparaginase
3
tislelizumab
2
camrelizumab
2
Lenalidomide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Azacitidine
2
toripalimab
1
tofacitinib
1
ruxolitinib
1
romidepsin
1
pembrolizumab
1
fludarabine phosphate
1
avelumab
1
apatinib
1
Thalidomide
1
Sensitivity and Specificity
1
Psychiatric Rehabilitation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Extranodal NK-T-Cell
×
ruxolitinib
×
Clear all
NCT04999878
2021-08-11
RUE-DDGP
Zhengzhou University
Phase 4
Unknown
30 enrolled